GleamWall
中文EN

LIMN Liminatus Pharma, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1971387 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,098.0%
TTM EPS YoY-860.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-471.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.12x
Interest coverage-53.78x

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-321.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$600,000$400,000————$0$357,066
SG&A expense$778,908$700,898$884,211$701,170$1.12M$264,220$167,077$186,081
Operating income-$1.38M-$1.10M-$884,211-$701,170-$1.12M-$264,220-$167,077-$543,147
Interest expense$18,844$18,638$19,051$19,052$62,288$115,512$106,164$92,706
Net income-$1.41M-$1.12M-$8.17M-$1.82M$113,287-$327,526-$229,752-$601,372
EBITDA-$1.38M-$1.10M-$883,668-$700,628————
EPS (basic)-0.03-0.03—-0.070.00-0.02—-0.03
EPS (diluted)-0.03-0.03—-0.070.00-0.02—-0.03
Weighted avg. shares (diluted)48.40M36.00M—27.01M23.30M17.50M—17.50M
Balance sheet
Cash & equivalents$3.02M$1.91M$337,655$724,502$1.34M$0$56,319—
Current assets$3.39M$2.78M$500,574$1.20M$1.78M—$5.28M—
PP&E, net$11,235$11,703$12,221$12,764$198—$941—
Total assets$3.40M$2.79M$512,795$1.34M$1.91M—$5.41M—
Current liabilities$3.04M$2.89M$10.30M$2.86M$10.52M—$24.75M—
Short-term debt$1.44M$1.44M$1.44M$1.44M$1.44M—$19.97M—
Total liabilities$3.10M$2.92M$10.33M$2.99M$10.72M$1,060$24.75M—
Shareholders' equity$300,612-$132,596-$9.81M-$1.65M-$8.81M-$19.67M-$19.34M-$19.11M
Shares outstanding55.97M44.88M27.06M27.06M26.01M—17.50M—
Cash flow statement
Operating cash flow-$969,999-$2.02M-$386,847-$600,612-$8.98M-$159,393-$140,660-$206,119
Capital expenditure——$0—————
Free cash flow——-$386,847—————
Investing cash flow——$0-$13,108-$200,000-$575,000-$550,000-$800,000
Financing cash flow$2.08M$3.59M$0$0$10.32M$713,000$700,000$1.02M
Depreciation & amortization$468$518$543$542————

Free plan shows the latest 8 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.